Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-PA02 in Cystic Fibrosis with Pseudomonas Aeruginosa
NCT04596319Phase 2Completed
- Sponsor
- Armata Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
A Phase 2 trial of AP-PA02 in Pseudomonas aeruginosa infection, sponsored by Armata Pharmaceuticals. Started Dec 2020; status: completed.
02
Drugs
AP-PA02
03
Conditions
Pseudomonas aeruginosa infection
Beyond the preview
Go deeper on NCT04596319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04596319.